As the Nasdaq and S&P 500 reach record highs, investors are keenly watching the Federal Reserve's upcoming interest rate decision, which could influence market dynamics. Penny stocks may be a throwback term, but the opportunities they represent are far from old news. Typically referring to smaller or newer companies, these stocks present an underappreciated chance for growth at lower price points.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.22 | $471.47M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.90 | $669.08M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $1.24 | $206.93M | ✅ 4 ⚠️ 2 View Analysis > |
| Puma Biotechnology (PBYI) | $4.64 | $225.16M | ✅ 3 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.8294 | $23.5M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 2 ⚠️ 5 View Analysis > |
| Table Trac (TBTC) | $4.70 | $23.8M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.9625 | $6.89M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.77 | $88.36M | ✅ 3 ⚠️ 3 View Analysis > |
| TETRA Technologies (TTI) | $4.89 | $630.41M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 379 stocks from our US Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Protalix BioTherapeutics (PLX)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system, with a market cap of $144.32 million.
Operations: The company generates revenue from its biotechnology segment, specifically focusing on startups, amounting to $61.95 million.
Market Cap: $144.32M
Protalix BioTherapeutics has recently turned profitable, reporting a net income of US$0.164 million in Q2 2025, compared to a loss the previous year. With no debt and strong short-term assets of US$65.5 million exceeding liabilities, its financial position is solid for a penny stock. The company's management and board are experienced, with an average tenure of over three years. Recent executive changes include appointing Gilad Mamlok as CFO, bringing extensive capital markets experience. Protalix's addition to multiple Russell indices highlights growing investor recognition despite low return on equity at 12.6%.
- Click here to discover the nuances of Protalix BioTherapeutics with our detailed analytical financial health report.
- Gain insights into Protalix BioTherapeutics' outlook and expected performance with our report on the company's earnings estimates.
ATRenew (RERE)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: ATRenew Inc. operates a platform for pre-owned consumer electronics transactions and services in China, with a market cap of approximately $969.17 million.
Operations: The company generates revenue from its retail electronics segment, totaling CN¥18.55 billion.
Market Cap: $969.17M
ATRenew Inc. has shown a strong turnaround, reporting a net income of CN¥72.34 million in Q2 2025, reversing from a loss the previous year. The company's robust financial health is supported by short-term assets of CN¥4.3 billion exceeding liabilities and operating cash flow covering debt significantly. Recent buyback activity, with 1.6 million shares repurchased for US$4 million, underscores management's confidence in its valuation, currently trading below estimated fair value. While earnings growth is expected to continue at an impressive rate annually, return on equity remains low at 5.5%, indicating room for improvement in generating shareholder returns.
- Click to explore a detailed breakdown of our findings in ATRenew's financial health report.
- Evaluate ATRenew's prospects by accessing our earnings growth report.
Voip-Pal.com (VPLM)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Voip-Pal.com Inc. focuses on acquiring and developing Voice-over-Internet Protocol processes in the United States, with a market cap of $35.82 million.
Operations: Voip-Pal.com Inc. has not reported any revenue segments.
Market Cap: $35.82M
Voip-Pal.com Inc., with a market cap of US$35.82 million, remains pre-revenue and unprofitable, having reported no significant revenue streams. Despite being debt-free and not diluting shareholders recently, the company faces financial challenges with less than a year of cash runway. Its short-term assets of US$1.3 million exceed liabilities, but high volatility persists in its share price. Recent earnings showed improvement with a net income of US$0.19 million for Q3 2025 compared to last year's loss; however, long-term profitability concerns remain due to increased losses over the past five years at an annual rate of 34.1%.
- Get an in-depth perspective on Voip-Pal.com's performance by reading our balance sheet health report here.
- Assess Voip-Pal.com's previous results with our detailed historical performance reports.
Seize The Opportunity
- Dive into all 379 of the US Penny Stocks we have identified here.
- Curious About Other Options? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if ATRenew might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com